Canterbury DHB


Tranexamic Acid

Anti-fibrinolytic treatment.

This is a synthetic derivative of the aminoacid lysine. Tranexamic acid, 4 -(aminomethyl) cyclohexanecarboxylic acid has antifibrinolytic activity in humans by binding reversibly to plasminogen, therefore blocking the binding of plasminogen to fibrin and its consequent activation to plasmin. Tranexamic acid is approximately 10 times more potent than aminocaproic acid (Amicar). This agent is effective even when bleeding is not associated with laboratory evidence of accelerated fibrinolysis. Mechanism of action thought to be inhibition of tissue fibrinolysis and consequent stabilisation of clots.

Adult doses: 1 g six to eight-hourly oral for 5 to 14 days.

In This Section


Side Effects


Side Effects

Dose-dependent side effects are predominantly gastrointestinal tract including nausea, vomiting, abdominal pain and diarrhoea. Theoretical risk of thrombotic side effects.

Caution in liver disease.

See the tranexamic acid Data Sheets on Medsafe.

About this Canterbury DHB document (5306):

Document Owner:

Sean Macpherson (see Who's Who)

Last Reviewed:

November 2019

Next Review:

November 2022


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 5306